DaShenLin Pharmaceutical Group Co., Ltd.

SHSE:603233 Stock Report

Market Cap: CN¥19.2b

DaShenLin Pharmaceutical Group Future Growth

Future criteria checks 3/6

DaShenLin Pharmaceutical Group is forecast to grow earnings and revenue by 21.9% and 16.6% per annum respectively. EPS is expected to grow by 21.4% per annum. Return on equity is forecast to be 17.4% in 3 years.

Key information

21.9%

Earnings growth rate

21.4%

EPS growth rate

Consumer Retailing earnings growth25.3%
Revenue growth rate16.6%
Future return on equity17.4%
Analyst coverage

Good

Last updated24 Mar 2025

Recent future growth updates

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

We Think DaShenLin Pharmaceutical Group (SHSE:603233) Can Stay On Top Of Its Debt

Mar 14
We Think DaShenLin Pharmaceutical Group (SHSE:603233) Can Stay On Top Of Its Debt

Potential Upside For DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Not Without Risk

Feb 14
Potential Upside For DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Not Without Risk

Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

Sep 30
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)

DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Sep 03
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Aug 20
DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital

Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Jun 17
Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%

Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Jun 09
Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?

Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

May 21
Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?

Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

May 06
Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings

Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Apr 09
Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital

Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Mar 17
Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E

Earnings and Revenue Growth Forecasts

SHSE:603233 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202749,7481,8223,192N/A2
12/31/202637,4951,6262,3824,13810
12/31/202532,0831,3712,0643,73610
12/31/202426,7791,1521,7823,2768
9/30/202426,5398501,4883,202N/A
6/30/202425,8859071,6343,464N/A
3/31/202425,3361,0682,0493,648N/A
12/31/202324,5311,1661,3773,174N/A
9/30/202324,1541,2872,0554,160N/A
6/30/202323,5191,2391,8463,815N/A
3/31/202322,5181,1482,5293,843N/A
12/31/202221,2481,0362,7223,757N/A
9/30/202219,2228961,2602,411N/A
6/30/202218,4258601,0272,237N/A
3/31/202217,3778353841,708N/A
12/31/202116,7597912601,555N/A
9/30/202116,4461,0136821,833N/A
6/30/202115,6971,1131,0972,066N/A
3/31/202115,2801,1221,2862,145N/A
12/31/202014,5831,0621,1621,954N/A
9/30/202013,5931,0141,4301,966N/A
6/30/202012,8299171,2291,759N/A
3/31/202011,9257991,2251,779N/A
12/31/201911,1417031,2061,708N/A
9/30/201910,6016741,1721,462N/A
6/30/201910,0296248521,285N/A
3/31/20199,4045696131,119N/A
12/31/20188,859532319874N/A
9/30/20188,421522-118663N/A
6/30/20188,003515N/A553N/A
3/31/20187,718505N/A511N/A
12/31/20177,421475N/A648N/A
9/30/20176,992462N/A545N/A
6/30/20176,824458N/A497N/A
3/31/20176,545433N/A502N/A
12/31/20166,274430N/A496N/A
6/30/20165,681427N/A406N/A
3/31/20165,464415N/A445N/A
12/31/20155,265395N/A469N/A
12/31/20144,545266N/A449N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603233's forecast earnings growth (21.9% per year) is above the savings rate (2.7%).

Earnings vs Market: 603233's earnings (21.9% per year) are forecast to grow slower than the CN market (23.6% per year).

High Growth Earnings: 603233's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 603233's revenue (16.6% per year) is forecast to grow faster than the CN market (12.6% per year).

High Growth Revenue: 603233's revenue (16.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603233's Return on Equity is forecast to be low in 3 years time (17.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/26 01:23
End of Day Share Price 2025/04/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DaShenLin Pharmaceutical Group Co., Ltd. is covered by 15 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Qianyi LiChina International Capital Corporation Limited
Mujun ShenCitic Securities Co., Ltd.
Zhu ChenCitic Securities Co., Ltd.